Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sen-Jam Pharmaceutical Enters Phase I Clinical Study on Alcohol Hangover Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sen-Jam Pharmaceutical Planning to Trial Oral COVID Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Duke University School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sen-Jam Pharmaceutical Partners with Leading Academic Medical Centers in Promising Novel Oral COVID-19 Therapeutic Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK-TECH, INC.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sen-Jam Pharmaceutical Partners with Specialty Pharmaceutical Manufacturer to Provide Formulation and Chemistry, Manufacturing & Controls for Covid-19 Oral Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alcohol Hangover Treatments and the Classification for Treating Hangovers as a Disease","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK-TECH, INC.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KVK Tech Announces Phase II Trial of COVID-19 Oral Therapy is Currently Enrolling in Nepal","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK-TECH, INC.","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sen-Jam Pharmaceutical Opens Enrollment for Patients in Their COVID Therapy Phase 2 Clinical Trial in Nepal and Engages With Strategic Investor for Worldwide Distribution","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK-Tech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sen-Jam Pharmaceutical Partners with Specialty Pharmaceutical Manufacturer to Provide Formulation and Chemistry, Manufacturing & Controls for Revolutionary Anti-Inflammatory Injectable","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Sen-Jam Pharmaceutical

    Menu

    Sen-Jam Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Sen-Jam Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sen-Jam Pharmaceutical Partners with Specialty Pharmaceutical Manufacturer to Provide Formulation and Chemistry, Manufacturing & Controls for Revolutionary Anti-Inflammator...

              Details:

              KVK-Tech will be providing formulation and Chemistry, Manufacturing & Controls for Sen-Jam's first injectable anti-inflammatory therapeutic, SJP-100, which reduces the rate at which inflammatory proteins are released into the body from the immune system.

              Lead Product(s): SJP-100

              Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-100

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: KVK-Tech

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership April 10, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sen-Jam Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sen-Jam Pharmaceutical Opens Enrollment for Patients in Their COVID Therapy Phase 2 Clinical Trial in Nepal and Engages With Strategic Investor for Worldwide Distribution

              Details:

              SJP-002C (ketotifen) world most potent, orally available anti-inflammatory a person could obtain for a mild to moderate coronavirus infection, Sen-Jam's investigational therapeutic for treatment of COVID-19, SJP-002C is now actively enrolling patients for their clinical trial.

              Lead Product(s): Ketotifen Fumarate,Indomethacin

              Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: KVK-TECH, INC.

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sen-Jam Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              KVK Tech Announces Phase II Trial of COVID-19 Oral Therapy is Currently Enrolling in Nepal

              Details:

              KVK will have exclusive manufacturing and supply rights for the product SJP-002C (Ketotifen) in the US. Sen-Jam will utilize the finished formulation and CMC report to enter licensing deals with contracting manufacturing companies (CMOs) globally.

              Lead Product(s): Ketotifen Fumarate,Indomethacin

              Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: KVK-TECH, INC.

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 05, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sen-Jam Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sen-Jam Pharmaceutical Partners with Specialty Pharmaceutical Manufacturer to Provide Formulation and Chemistry, Manufacturing & Controls for Covid-19 Oral Therapeutic

              Details:

              Sen-Jam Pharmaceutical has entered a development, manufacturing, distribution, and license agreement with KVK-Tech. This is a monumental milestone for the company and great news for their promising oral COVID-19 treatment, SJP-002C.

              Lead Product(s): Ketotifen Fumarate,Indomethacin

              Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: KVK-TECH, INC.

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership March 22, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sen-Jam Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Alcohol Hangover Treatments and the Classification for Treating Hangovers as a Disease

              Details:

              Results from a recent pilot study showed that SJP-001, comprising a combination of naproxen and fexofenadine was significantly more effective in reducing alcohol hangover severity than placebo.

              Lead Product(s): Naproxen,Fexofenadine Hydrochloride

              Therapeutic Area: Psychiatry/Psychology Product Name: SJP-001

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 17, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sen-Jam Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sen-Jam Pharmaceutical Partners with Leading Academic Medical Centers in Promising Novel Oral COVID-19 Therapeutic Clinical Trial

              Details:

              The collaboration received official approval this past Friday from the Nepal Health Research Council and is now commencing Phase II Clinical Trials of SJP-002C, for a novel oral therapy to mitigate the symptoms and hospitalizations associated with COVID-19.

              Lead Product(s): Ketotifen Fumarate,Indomethacin

              Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Duke University School of Medicine

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration February 22, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sen-Jam Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sen-Jam Pharmaceutical Planning to Trial Oral COVID Therapy

              Details:

              Sen-Jam’s investigational therapeutic for COVID-19, SJP-002C is scheduled to begin a clinical trial in December 2021 under a co-development agreement with Duke-NUS. SJP-002C is a potent anti inflammatory with antiviral capabilities and minimal side effects.

              Lead Product(s): SJP-002C

              Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 12, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sen-Jam Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sen-Jam Pharmaceutical Enters Phase I Clinical Study on Alcohol Hangover Treatment

              Details:

              Sen-Jam has an open FDA Investigational New Drug (IND) application to begin a phase I clinical study for SPJ-001 and is in late-stage discussions with a US Licensee for distribution.

              Lead Product(s): SPJ-001

              Therapeutic Area: Psychiatry/Psychology Product Name: SPJ-001

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 23, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY